GlycoNex Showcases Promising Preclinical Findings for Novel ADC GNX1021 Targeting Gastric Cancer

GlycoNex Unveils Promising Results for GNX1021 in Gastric Cancer Treatment

GlycoNex, Inc., a progressive biotechnology firm based in New Taipei City, has revealed groundbreaking outcomes from its preclinical studies regarding the novel antibody-drug conjugate (ADC) GNX1021, designed to combat gastric cancer. This innovative compound has demonstrated remarkable efficacy, showcasing potent inhibition of tumor growth in animal models of gastric cancer. As part of its commitment to oncology advancements, GlycoNex aims to provide effective alternatives for patients who are unsuitable for current HER2 or CLDN18-targeted therapies. Moreover, the expansive activity of GNX1021 hints at potential treatments for various solid tumors.

In preliminary safety evaluations, GNX1021 underwent a pilot toxicology study using cynomolgus monkeys, resulting in a safety profile similar to existing ADCs that have received approval. GlycoNex is on track to initiate Good Laboratory Practice (GLP)-compliant toxicology studies by the end of this year and plans to file clinical trial applications in Taiwan and Japan in the first quarter of 2026. The company is enthusiastic about beginning Phase I human trials in the following quarter, marking a vital step towards bringing this promising therapy to patients.

Dr. Mei-Chun Yang, GlycoNex's CEO, expressed optimism regarding the rapid progress of the GNX1021 program, emphasizing the company's expertise in antibody-drug development. She highlighted the importance of pursuing early-stage licensing and strategic collaborations to secure upfront funding, reduce development risks, and accelerate the timeline towards clinical application. This proactive approach aligns with recent substantial deals within the ADC realm, where asset licensing has amounted to billions in valuations. With the global ADC market exceeding USD 160 billion in 2023, GlycoNex is determined to harness this opportunity, advancing innovation in cancer treatment and addressing significant unmet medical needs.

GlycoNex will also participate in the upcoming BIO International Convention scheduled for June 2025. This event will serve as a platform for the company to engage with international pharmaceutical partners, further discussing potential collaborations and partnerships to expedite the development of GNX1021.

About GlycoNex Inc.

GlycoNex Inc. stands at the forefront of developing glycan-directed cancer immunotherapies, aiming to inhibit tumor growth effectively while minimizing adverse effects. The company maintains a robust pipeline of therapies, including GNX102, a humanized monoclonal antibody that targets atypical sugar molecules found in cancer cells. This principal candidate has successfully completed Phase 1 trials, displaying excellent safety and positive efficacy results. Additionally, GlycoNex's portfolio comprises various ADCs designed to precisely attack cancer cells without harming healthy tissues, such as the innovative GNX1021, targeting branched Lewis B/Y (bLeB/Y).

For more information about GlycoNex and its advancements in biotechnology, visit GlycoNex's official website.